Abstract.-This paper describes the synthesis and biological activity of [5-L-asparagine-a4,34,3-d3]-deamino-oxytocin. The model peptide S-benzyl-3-mercaptopropionyl-L-asparaginyl-a4,3,-d3-glycinamide was also prepared to observe the effect of the conditions of peptide synthesis on the deuterium content. It was found that normal synthetic procedures could be used without a significant loss in the deuterium content.
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The [5-L-asparagine-a,,S,-d3 1-deamino-oxytocin had, within experimental error, the same avian vasodepressor and oxytocic activities as deamino-oxytocin itself.
In a continuation of a program to evaluate the effect on the biological activity of deamino-oxytocin ( (1) Synthesis of N-carbobenzoxy-L-asparagine-a,,f-d3 (II) and p-nitrophenyl N-carbobenzoxy-L-asparaginate-a,fid-d3 (III): The procedure reported for the protio analog was followed.4 L-Asparagine-a,#,#-d3,5 2.0 gm (0.015 mole), 3 A modification of the procedure reported for the protio analog was followed.4 A solution of 2.30 gm (0.008 mole) of the acid II, 1.45 gm of p-nitrophenol, and 1.95 gm of dicyclohexylcarbodiimide (DCC) in 18 ml of dimethylformamide (DMF), dried and freshly distilled,6 was stirred for 1 hr at 00 and at room temperature for 15 min. Glacial acetic acid (0.3 ml) was added, the solution was stirred for 15 min, cooled to -20°, and filtered. The product III was precipitated by the addition of 70 ml of water, and was isolated by filtering the cooled mixture. After being dried in vacuo for 24 hr, there was A solution of the dipeptide IV (0.40 gm, 1.23 mmole) in 10 ml of acetic acid and 10 ml of 32% HBr/HOAc was stirred for 1 hr. The hydrobromide salt was precipitated with 250 ml of ether, collected on a glass filter, and dried. The salt was neutralized by dissolving in methanol and eluting through a column of Rexyn 201 (OH cycle). The methanol solution was evaporated to dryness in vacuo to give 0.23 gm (100%) of the free dipeptide. The free dipeptide was dissolved in DMF and p-nitrophenyl S-benzyl-fl-mercaptopropionate (0.4 gm, 1.8 mmole) was added. The solution was stirred for 1 hr and evaporated to dryness in vacuo. The residue was crystallized from methanol to give 0.34 gm (74%) of S-benzyl-,-mercaptopropionyl-L-asparaginyl-a,,B,-drglycinamide (V) :3 mp 185-186°; IR (KBr) 2.9, 3.0, 3.2, 3.4, 6.05, and 6.45 ,u. Analysis showed the compound to be 93% deuterated.
(3) Preparation of the crystalline deuterated deamino-oxytocin 1: The reported procedure for the stepwise synthesis of the requisite protected polypeptide precursor for compound I was followed.7 The following protected deuterated peptide intermediates were characterized: (a) N-carbobenzoxy-Lasparaginyl-a,fB-da-S-benzyl-cysteinyl-iprolyl- The protected polypeptide, S-benzyl-j3
gave difficulty in purification. The preparation and purification of the deuterated deamino-oxytocin, however, was continued following the reported procedures.8 The protected polypeptide X (240 mg) was reduced with sodium in liquid ammonia followed by oxidative cyclization of the resulting deamino-oxytoceine. Purification of the deuterated analog I was accomplished by partition chromatography on Sephadex 0-25 with the solvent system 1-butanol-benzene-water containing 3.5 per cent acetic acid and 1.5 per cent pyridine (1:1:2), Rf = 0.18,9 followed by gel filtration on Sephadex 0-25 (elution volume = 345 ml)10 gave 37 mg (22%) of lyophilized powder of the compound I. This powder was then crystallized twice from deionized water and dried to constant weight, as previously reported, to give 15.9 mg (9.4%) of crystalline I: mp 185-186O (cor). Analy- (4) Biological activty determinations; Avian vasodepressor assays were performed on conscious chickens according to the reported procedure." Oxytocic assays were performed on isolated uteri from rats in natural estrus according to the method of Holton,12 as modified by the technique of Munsick, 13 with the use of magnesium-free van DykeHastings solution as the bathing fluid. The four-point assay design'4 was used in all bioassays with crystalline deamino-oxytocin as standard. The activity values reported earlier8 for deamino-oxytocin were used in the calculations. They are 803 U/mg of oxytocic activity and 975 U/mg of avian vasodepressor activity. Standard errors were calculated to 95% confidence limits. The deuterated analog I had 827 ± 10 U/mg (14-4 points) oxytocic activity and 1000 ± 17 U/mg (13-4 points) avian vasodepressor activity.
Discussion of Results.-A simple deuterated peptide was prepared prior to the synthesis of the analog I in order to observe the effect of the removal of the carbobenzoxy protecting groups and the several coupling reactions on the deuterium content of the asparagine in the desired deamino-oxytocin I. This work is summarized in Figure 2 . The p-nitrophenyl ester III and glycinamide were coupled to give the protected dipeptide IV with no loss of deuterium. Removal of the carbobenzoxy group of IV with hydrogen bromide in acetic acid followed by coupling with p-nitrophenyl S-benzyl-f3-mercaptopropionate gave the tripeptide gly(NH,) CbzNHCDCO 2% D) ; the protected hexapeptide VII (94.5% D); and the protected heptapeptide VIII (96% D). These data, plus previous findings,' insured that the final product, analog I, would be highly deuterated. It was thus established that deuterated amino acids can be incorporated into peptides by normal synthetic procedures without a measurable loss of deuterium content.
The biological activities were determined as described (supra vide). The [5-L-
